Prior studies have evaluated the efficacy of Akt inhibitors in a range of cancers, where promising results had been obtained in preclinical models using drug combinations that include Akt inhibitors, such as AZD5363 combined with fulvestrant in endocrine-resistant breast cancer47, and AZD5363 combined with AZD8931, an EGFR/ErbB2/ErbB3 inhibitor, in ErbB2-amplified breast cancer48. The gene discussed is ERBB3; the disease is cancer.